#United States #New York #Pomerantz #Ultragenyx #RARE

Investigation into Ultragenyx Pharmaceutical Inc.

Pomerantz LLP, a renowned law firm located in major cities such as New York, Chicago, and London, is currently probing claims related to Ultragenyx Pharmaceutical Inc. (trading on NASDAQ as RARE). The firm is reaching out to investors who may have been negatively affected by the company's actions and business practices.

Background on Ultragenyx Pharmaceutical

Ultragenyx specializes in developing innovative biopharmaceuticals aimed at treating rare diseases. Recently, the company faced significant scrutiny after announcing results from two Phase 3 clinical trials on their drug, setrusumab, which targets bone metabolism disorders. While the secondary endpoints demonstrated improvements in bone mineral density, neither trial achieved the primary endpoints regarding the reduction of clinical fractures.

The Stock Market Reaction

Following the announcement on December 29, 2025, Ultragenyx's stock plummeted dramatically—dropping $2.02 per share, which represented an 87.64% decline, closing at just $0.28 per share. This shocking decline raised immediate concerns regarding possible securities fraud and whether the company, along with its top executives and board members, were involved in unlawful business practices impacting investors.

Legal Implications

Investors are being urged to seek legal advice if they believe they have been wronged by Ultragenyx's handling of the situation. Danielle Peyton from Pomerantz LLP is spearheading the investigation and can be contacted for additional information. The law firm has a long-standing history of advocating for victims of corporate misconduct, recovering substantial damages for class action members.

Pomerantz's Reputation

Founded by Abraham L. Pomerantz, known as a leading figure in the class action sphere, the firm is recognized for its expertise in securities class litigation. Its commitment to fighting against breaches of fiduciary duty showcases its dedication to protecting investors' rights and pursuing justice.

Conclusion

As this investigation unfolds, the impact on Ultragenyx and its stockholders will be closely monitored. Investors are advised to stay informed about the investigation's progress and consider their legal options if they feel their interests have been compromised. The case exemplifies the critical need for corporate accountability in the pharmaceutical industry, especially regarding how drug trial results are communicated to investors and the public.

Overall, the current situation surrounding Ultragenyx raises crucial questions about the integrity of publicly traded companies and the importance of transparent practices in maintaining investor trust.